Market News & Trends
Biosimilars Market Expected to Soar
Top representatives from the healthcare industry were confirmed to attend the 2nd Biosimilars Congregation which took place in London on February 19 and 20.…
Nexavar Continues to Dominate Advanced Liver Cancer Therapy
Hepatocellular carcinoma (HCC), the most common form of liver cancer, carries a deadly reputation, and patients face shrinking hopes of new treatment options as…
Opioid Drug Abuse Will be Tackled Through New Delivery Methods
The opioid pain management market will continue to evolve throughout the coming years with new products and post-marketing studies that aim to reduce the…
Third Rock Ventures Launches Cancer Immunotherapeutics Company With $47 Million
Third Rock Ventures, LLC recently announced the formation of Jounce Therapeutics, Inc. with a $47 million Series A financing of the company. Jounce is…
Perrigo Buys Company for $283 Million
Perrigo Company recently announced it has signed a definitive merger agreement and has completed the acquisition of Leeds, U.K.-based Rosemont Pharmaceuticals Ltd. for approximately…
Second Expansion Underway for Rexam Healthcare
Four years after its first extension, Rexam is again expanding its La Verpillière site (near Lyon) to create a building including approx. 2400 m2…
Xenon Receives Major Milestone for Marketing Approval
Xenon recently announced it has received a milestone payment from uniQure BV for the European Commission marketing approval of Glybera, a novel gene therapy…
2/13/2013
Frost & Sullivan Sees Urgent Need for Cancer Diagnostics Tests; Finds Unmet Need for Key Disorders The range of potential therapeutic approaches available to treat…
Frost & Sullivan Sees Urgent Need for Cancer Diagnostics Tests; Finds Unmet Need for Key Disorders
The range of potential therapeutic approaches available to treat cancer is expected to expand rapidly during the next decade. Current diagnostic technologies focus on…
Lycera Expands Partnership With Merck; Potential $600-Million Deal
Lycera Corp. recently announced a collaboration agreement with Merck to discover, develop, and commercialize small-molecule therapies directed to selected novel targets being investigated for…
Novozymes Biopharma Announces Agreement With EpiVax
Novozymes Biopharma recently announced a collaborative research agreement with Rhode Island-based biotech company, EpiVax, Inc. to help further the development of a potential paradigm-shifting…
2/6/2013
Foresite Capital Closes $100 Million Fund for Late-Stage Biotechs Biotech venture capital isn't what it used to be, but there's still money to invest in…
Bend Research Receives EU Certificate
Bend Research Inc. recently announced it has received certification of compliance with European Union (EU) Good Manufacturing Practice (GMP) regulations. This broad certification, which…
CROs Offer Promise of Innovative, Safe & Effective Development
Pharmaceutical and biotech companies are outsourcing research in order to develop innovative products that meet the rising demand for therapeutics across a range of…
Foresite Capital Closes $100 Million Fund for Late-Stage Biotechs
Biotech venture capital isn't what it used to be, but there's still money to invest in healthcare. Now one biotech investment firm just starting…
Generic Statins to Slash Global Market Value
The introduction of generic statins has kick-started a decline that will see the global statins market lose more than $7 billion in revenue by 2018,…
Patheon Makes Investment to Expand Early Development Capabilities
Patheon Inc. recently announced plans for additional investment in its Milton Park facility. Located in Oxfordshire, UK, Milton Park is a dedicated pharmaceutical development…
Tapemark Expands Transdermal Patch Capabilities
Tapemark recently announced the addition of several new capabilities for transdermal patches, including the formulation, blending, and coating steps in the patch manufacturing process.…
Threshold Pharmaceuticals Earns $30-Million Milestone Payment
Threshold Pharmaceuticals, Inc. recently announced that its partner Merck KGaA, Darmstadt, Germany, through its division Merck Serono, initiated the global Phase III MAESTRO study…
1/30/2013
Baxter International Makes $700-Million Acquisition Inspiration Biopharmaceuticals and Ipsen recently announced the sale of its lead hemophilia program, OBI-1 (recombinant porcine factor VIII), to Baxter…
